These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32935346)

  • 21. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
    Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
    Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
    Schey R; Alla SP; Midani D; Parkman HP
    Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art.
    Savarino V; Marabotto E; Zentilin P; Demarzo MG; de Bortoli N; Savarino E
    Drug Des Devel Ther; 2021; 15():1609-1621. PubMed ID: 33907381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescribing Patterns of Proton Pump Inhibitors in Germany: A Retrospective Study Including 472 146 Patients.
    Plehhova K; Haering M; Wray J; Coyle C; Ibáñez E; Kostev K
    J Prim Care Community Health; 2023; 14():21501319231221002. PubMed ID: 38142444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Factors affecting efficacy of gastroesophageal reflux disease treatment with proton pump inhibitors].
    Ter Arkh; 2012; 84(2):16-21. PubMed ID: 22715656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-
    Modak AS; Klyarytska I; Kriviy V; Tsapyak T; Rabotyagova Y
    J Breath Res; 2016 Dec; 10(4):046017. PubMed ID: 27991432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
    Azzam RS
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
    Higginbotham TW
    Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.
    Habu Y
    Intern Med; 2019 Sep; 58(17):2427-2433. PubMed ID: 31178490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological management of GERD: where does it stand now?
    Hershcovici T; Fass R
    Trends Pharmacol Sci; 2011 Apr; 32(4):258-64. PubMed ID: 21429600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
    Maev IV; Balashova NN; Busarova GA
    Klin Med (Mosk); 2003; 81(9):54-9. PubMed ID: 14598594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proton pump inhibitors in the management of GERD.
    Katz PO; Zavala S
    J Gastrointest Surg; 2010 Feb; 14 Suppl 1():S62-6. PubMed ID: 19774429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.
    Hillman L; Yadlapati R; Thuluvath AJ; Berendsen MA; Pandolfino JE
    Dis Esophagus; 2017 Sep; 30(9):1-15. PubMed ID: 28859358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of proton pump inhibitors in children: a comprehensive review.
    Gibbons TE; Gold BD
    Paediatr Drugs; 2003; 5(1):25-40. PubMed ID: 12513104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J; Dodd S; Durkin M; Sloan S
    Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection.
    Teng M; Khoo AL; Zhao YJ; Lin L; Lim BP; Wu TS; Dan YY
    J Clin Pharm Ther; 2015 Aug; 40(4):368-75. PubMed ID: 25893507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.